title: Long-term benefit of reduced intraocular pressure in primary open-angle glaucoma patients in Ethiopia.
abstract: OBJECTIVE
  To determine the incidence of progression of primary open-angle glaucoma at individual levels of mean intraocular pressure (IOP) in patients in Ethiopia.
  
  
  METHODS
  A retrospective, multicenter, cohort analysis of patient records with at least 5 years of potential follow-up were evaluated for risk factors associated with progressive optic disc and visual field loss.
  
  
  RESULTS
  There were 300 patients with the potential of 5 years of follow-up. In total, 166 patients progressed before 5 years and 134 remained stable for the full 5-year follow-up period. Of the total sample, 84% of patients with IOPs < or =19 (n=117/139), 53% of patients with IOPs of 20 (n=9/17), 14% of patients with IOPs of 21-24 (n=9/63), and 0% of the patients with IOPs of > or =25 mmHg (n=0/79) remained stable over at least 5 years. The mean IOP was 17.4+/-2.1 in the stable group and 25.0+/-5.9 mmHg in the progressed group (p<0.0001). The highest average peak IOP was 24.5+/-4.5 in the stable group and 29.0+/-6.1 mmHg in the progressed group (p<0.0001). A multivariant regression analysis to determine risk factors for progression was positive for mean IOP (p=0.0097).
  
  
  CONCLUSIONS
  This study suggests that IOP reduction in a developing country, despite potential limitations in diagnostic techniques, follow-up, and compliance, can be effective in reducing the risk of glaucomatous progression over long-term follow-up.
authors.affiliation: Ras Desta Hospital, Addis Ababa, Ethiopia.
authors.forename: Abiye M
authors.initials: AM
authors.lastname: Alemu
authors.forename: Caroline J
authors.initials: CJ
authors.lastname: Kristoffersen
authors.forename: Michael S
authors.initials: MS
authors.lastname: Kristoffersen
authors.forename: Jeanette A
authors.initials: JA
authors.lastname: Stewart
authors.forename: William C
authors.initials: WC
authors.lastname: Stewart
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D018450:Disease Progression; D005002:Ethiopia / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000453:epidemiology / Q000503:physiopathology* / Q000628:therapy; D006068:Gonioscopy; D006801:Humans; D015994:Incidence; D007429:Intraocular Pressure / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D042262:Retinoscopy; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D014130:Trabeculectomy / Q000379:methods
chemical_list: D000959:Antihypertensive Agents